Health Care • Biotechnology: Pharmaceutical Preparations
$2.54 ▼ -0.04
(-1.55%)
MKT CAP: $278.8M • VOL: 1.83M
52W L $2 52W H $5
RCKT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$231.7M | -$273.2M | -$259.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$223.1M | -$258.7M | -$245.6M |
| EBITDA (Normalized) | -$231.4M | -$268.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$190.0M | -$209.7M | -$194.9M |
| Capital Expenditures (CapEx) | $440.0K | $5.9M | — |
| Free Cash Flow (FCF) | -$190.5M | -$215.6M | -$194.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $77.6M | $163.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $277.2M | $463.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RCKT.